{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:48:00Z","timestamp":1789015680569,"version":"build-2803163510"},"reference-count":61,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Nodular lymphocyte\u2010predominant Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">NLPHL<\/jats:styled-content>) is a unique rare subtype of Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>) which differs clinically, pathologically and biologically from classic <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>, warranting a nuanced approach to treatment. <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>20 expression by malignant lymphocyte\u2010predominant cells, a tendency for late relapses, and the risk of transformation to aggressive large B\u2010cell lymphoma are characteristic features with important implications for treatment and follow\u2010up. Recognition of histopathological variant patterns is also critical, with important implications for prognosis and treatment. The optimal management for <jats:styled-content style=\"fixed-case\">NLPHL<\/jats:styled-content> is unclear and opinions differ as to whether treatment paradigms should be similar to, or differ from, those for classic <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>. Therapy differs for early <jats:italic>versus<\/jats:italic> advanced stage disease and for frontline <jats:italic>versus<\/jats:italic> relapsed or refractory disease. Potential treatment strategies include radiotherapy, combined modality therapy, chemotherapy, rituximab and watchful waiting. Given the excellent overall survival of <jats:styled-content style=\"fixed-case\">NLPHL<\/jats:styled-content>, treatment choices should be geared towards reducing long\u2010term toxicity and optimizing survivorship. In this review, we provide an overview of the current literature and discuss modern principles in the management of <jats:styled-content style=\"fixed-case\">NLPHL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.15616","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T17:51:52Z","timestamp":1543427512000},"page":"17-29","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Modern principles in the management of nodular lymphocyte\u2010predominant Hodgkin lymphoma"],"prefix":"10.1111","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5013-4651","authenticated-orcid":false,"given":"Michael A.","family":"Spinner","sequence":"first","affiliation":[{"name":"Division of Oncology Department of Medicine Stanford University Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Varma","sequence":"additional","affiliation":[{"name":"Department of Medicine New York\u2010Presbyterian Hospital\/Weill Cornell Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"Division of Oncology Department of Medicine Stanford University Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-453241"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.2069"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24927"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.9516"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1383"},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood.V126.23.3863.3863","article-title":"Outcomes of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) vs. classical Hodgkin lymphoma (cHL) at Princess Margaret Cancer Centre","volume":"126","author":"Ames J.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11661"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.3469"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24819"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07963.x"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood.V130.Suppl_1.654.654","article-title":"Active surveillance for newly diagnosed nodular lymphocyte\u2010predominant Hodgkin lymphoma","volume":"130","author":"Borchmann S.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0626"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20080809"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3293"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14001"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1124993"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.0945"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.776"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.324"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-361055"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.4363"},{"key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood.V128.22.922.922","article-title":"Relapsed nodular lymphocyte\u2010predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group (GHSG)","volume":"128","author":"Eichenauer D.A.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.321"},{"key":"e_1_2_11_25_1","first-page":"P275","article-title":"Long\u2010term outcome of patients with nodular lymphocyte\u2010predominant Hodgkin lymphoma teated within the randomized HD7\u2010HD15 trials: an analysis from the German Hodgkin Study Group (GHSG)","volume":"102","author":"Eichenauer D.A.","year":"2017","journal-title":"Haematologica"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy080"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000067"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23989"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200310000-00007"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-766121"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0567"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.02.012"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13087"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.09.049"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-515825"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078812"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12997"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13310"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0013"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.03.008"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665505"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22762"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7535"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi323"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8869"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1065978"},{"key":"e_1_2_11_48_1","first-page":"1","article-title":"R\u2010Bendamustine in the treatment of nodular lymphocyte\u2010predominant Hodgkin lymphoma","author":"Prusila R.","year":"2018","journal-title":"Acta Oncologica"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/13.S1.44"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-365932"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200209000-00008"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-078725"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.10.018"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13540"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14861"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.94"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.05.005"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10404"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21303"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.1819"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-541078"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15616","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T12:07:21Z","timestamp":1694606841000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1111\/bjh.15616"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15616","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,28]]},"assertion":[{"value":"2018-11-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}